Join the Beyfortus group to help and get support from people like you.
Beyfortus News
More Than Half of Infants Protected by Maternal RSV Vaccine, Nirsevimab, or Both
FRIDAY, Sept. 27, 2024 – In the 2023 to 2024 respiratory syncytial virus (RSV) season, more than half of infants were protected by maternal RSV vaccine, nirsevimab, or both, according to research...
Nirsevimab Effective Against RSV-Linked Bronchiolitis Hospitalization
WEDNESDAY, July 10, 2024 – Nirsevimab therapy is effective for reducing the risk for hospitalization for respiratory syncytial virus (RSV)-associated bronchiolitis among infants, according to a...
FDA Approves Beyfortus (nirsevimab) for the Prevention of RSV Lower Respiratory Tract Disease in Infants
July 17, 2023 – AstraZeneca and Sanofi’s Beyfortus (nirsevimab) has been approved in the US for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns ...